EQL Pharma AB Stock: price and insider trades · Sweden

EQL Pharma AB is a Health Care company. Its directors and officers file their transactions with Finansinspektionen. Over the twelve months to 18 October 2026, 4 filings were filed, from 4 insiders.

Open-market activity splits into 3 purchases totalling €145k and 1 sale totalling €113k; 3 insiders sit on the buying side and 1 insider on the selling side. The net balance comes to €32k on the buying side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The buyers include 2 board members and 1 finance chief. The largest single trade was a sale of €113k by Axel Schörling, published on 27 March 2026, equal to 0.17% of the market capitalisation.

Across the 890 companies tracked on its exchange, the median is 7 filings; at 4 filings, this issuer sits below that mark. Since 2025, the database holds 7 purchases and 2 sales by insiders of the company.

In the case of 1 purchase, another manager of the company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The clock since the last published purchase (17 August 2026) now reads 61 days. Publication is fast: at least half of the trades appear on Finansinspektionen on the same day. The legal deadline for notifying a trade is three business days (MAR article 19).

Other companies in the same sector with recent insider buying flagged by our signals: Anixa Biosciences Inc and Vivos Inc. These figures are compiled from regulatory filings published by Finansinspektionen. They describe what insiders did and are not a recommendation.